Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Buys Dx Rights to Genizon Research Programs, Takes Equity Stake in Firm

NEW YORK (GenomeWeb News) - Genizon Biosciences and pharmaceutical giant Pfizer have reached a licensing and collaboration agreement that gives Pfizer diagnostic rights to Genizon's research programs in Alzheimer's, attention deficit hyperactivity disorder, and endometriosis.
 
Pfizer has agreed to pay Genizon upfront license fees and will also fund the company’s research on genetic variations associated with those diseases. Pfizer will also buy an equity stake in the company, subject to certain closing conditions.
 
Genizon retains therapeutic rights to the research programs.
 
The companies will collaborate on the discovery of diagnostic markers based on Genizon’s ongoing genome-wide association studies of the Quebec Founder Population. Genizon said that the "unique genetic heritage" of the Quebec Founder Population offers opportunities to find genetic markers to predict disease susceptibility.
 
The companies plan to compare the data derived from these studies against data from other genome-wide association studies from conducted in "general populations."

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.